XWPharma
PrivateLast Round
Series C
Sep 17, 2020
Total Funding Raised
$57.5M
Momentum Score
75 /100
Company Overview
XWPharma is a biotechnology company focused on developing innovative therapeutics to address sleep, neuropsychological, and other neglected central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Mental Health
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
XWPharma Comps
Public and private peers based on sector, stage, and business model.
XWPharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 17, 2020 | ||||
| Series B | Sep 20, 2017 |
XWPharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| WI Harper Group | Series C |
| Orient Hontai Capital | Series C |
| KTB Ventures | Series B, Series C |
| Trinity Innovation Fund | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 17, 2026
Grew 37% QoQ, from 19 to 26 employees.
- Apr 18, 2026
Grew 35% QoQ, from 17 to 23 employees.
XWPharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about XWPharma's valuation, stock price, and market status.
